- Home
- MYD vs RGNX Comparison
MYD vs RGNX Comparison
Compare MYD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYD
- RGNX
- Stock Information
- Founded
- MYD 1991
- RGNX 2008
- Country
- MYD United States
- RGNX United States
- Employees
- MYD N/A
- RGNX N/A
- Industry
- MYD Investment Bankers/Brokers/Service
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYD Finance
- RGNX Health Care
- Exchange
- MYD Nasdaq
- RGNX Nasdaq
- Market Cap
- MYD 482.9M
- RGNX 387.0M
- IPO Year
- MYD N/A
- RGNX 2015
- Fundamental
- Price
- MYD $9.92
- RGNX $5.94
- Analyst Decision
- MYD
- RGNX Strong Buy
- Analyst Count
- MYD 0
- RGNX 8
- Target Price
- MYD N/A
- RGNX $31.75
- AVG Volume (30 Days)
- MYD 253.1K
- RGNX 1.1M
- Earning Date
- MYD 01-01-0001
- RGNX 05-07-2025
- Dividend Yield
- MYD 4.55%
- RGNX N/A
- EPS Growth
- MYD N/A
- RGNX N/A
- EPS
- MYD N/A
- RGNX N/A
- Revenue
- MYD N/A
- RGNX $83,328,000.00
- Revenue This Year
- MYD N/A
- RGNX $285.14
- Revenue Next Year
- MYD N/A
- RGNX N/A
- P/E Ratio
- MYD N/A
- RGNX N/A
- Revenue Growth
- MYD N/A
- RGNX N/A
- 52 Week Low
- MYD $8.76
- RGNX $5.04
- 52 Week High
- MYD $11.30
- RGNX $17.99
- Technical
- Relative Strength Index (RSI)
- MYD 35.95
- RGNX 42.51
- Support Level
- MYD $9.65
- RGNX $5.04
- Resistance Level
- MYD $10.13
- RGNX $6.83
- Average True Range (ATR)
- MYD 0.23
- RGNX 0.61
- MACD
- MYD -0.04
- RGNX -0.05
- Stochastic Oscillator
- MYD 23.89
- RGNX 37.32
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.